Anika Therapeutics, Inc. (ANIK)
| Market Cap | 277.03M +115.9% |
| Revenue (ttm) | 120.65M +5.3% |
| Net Income | -3.78M |
| EPS | -0.28 |
| Shares Out | 13.38M |
| PE Ratio | n/a |
| Forward PE | 23.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,522 |
| Open | 20.81 |
| Previous Close | 20.81 |
| Day's Range | 20.45 - 21.14 |
| 52-Week Range | 8.67 - 22.88 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 22.00 (+6.28%) |
| Earnings Date | Nov 4, 2026 |
About ANIK
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and ... [Read more]
Financial Performance
In 2025, Anika Therapeutics's revenue was $112.82 million, a decrease of -5.91% compared to the previous year's $119.91 million. Losses were -$10.88 million, -80.70% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price target is $22.0, which is an increase of 6.28% from the latest price.
News
Anika Therapeutics assumed with a Buy at B. Riley
B. Riley assumed coverage of Anika Therapeutics (ANIK) with a Buy rating with a price target of $23, up from $21. Anika’s operational turnaround is driving a meaningful earnings recovery,…
Anika Therapeutics price target raised to $21 from $18 at B. Riley
B. Riley raised the firm’s price target on Anika Therapeutics (ANIK) to $21 from $18 and keeps a Buy rating on the shares. Anika delivered a strong Q2 beat with…
Anika Therapeutics price target raised to $21 from $17 at Barrington
Barrington raised the firm’s price target on Anika Therapeutics (ANIK) to $21 from $17 and keeps an Outperform rating on the shares. The company reported a Q2 beat and increased…
Anika Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw 16% revenue growth, record international sales, and gross margin expansion to 65%. Full-year guidance was raised for revenue and profitability, driven by strong product and geographic performance, operational improvements, and pipeline progress.
Anika Therapeutics Earnings release: Q2 2026
Anika Therapeutics released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Anika Therapeutics Slides: Q2 2026
Anika Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Anika Therapeutics Quarterly report: Q2 2026
Anika Therapeutics has published its Q2 2026 quarterly earnings report on July 29, 2026.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
BEDFORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its...
Anika Therapeutics Transcript: AGM 2026
The meeting covered board introductions, five key proposals, and voting procedures. All proposals, including director elections, auditor ratification, executive compensation, and plan amendments, passed by majority vote. No questions were submitted by stockholders.
Anika Therapeutics Proxy statement: Proxy filing
Anika Therapeutics filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early inte...
Anika Therapeutics Proxy statement: Proxy filing
Anika Therapeutics filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Anika Therapeutics reports Q1 EPS 27c vs.(6c) last year
Reports Q1 revenue $29.6M vs. $26.2M last year. Reports total company revenue grew 13%, driven by commercial channel strength and favorable OEM channel order timing. “Our strategic transformation and ...
Anika Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 13% year-over-year to $29.6 million, driven by strong commercial and OEM channels, improved gross margin, and accelerating Integrity adoption. Full-year guidance is maintained, with continued investment in innovation and operational efficiency.
Anika Therapeutics Earnings release: Q1 2026
Anika Therapeutics released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Anika Therapeutics Slides: Q1 2026
Anika Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Anika Therapeutics Quarterly report: Q1 2026
Anika Therapeutics has published its Q1 2026 quarterly earnings report on April 29, 2026.
Anika Reports First Quarter 2026 Financial Results
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execut...
Anika Therapeutics Proxy statement: Proxy filing
Anika Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Anika Therapeutics Proxy statement: Proxy filing
Anika Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue it...
Anika Therapeutics Transcript: 2026 CG Musculoskeletal Conference
The conference highlighted a robust hyaluronic acid-based product portfolio, strong commercial growth, and a focus on expanding regenerative solutions. Regulatory progress for Hyalofast and Cingal, along with disciplined R&D and operational improvements, support a positive outlook.
Anika Therapeutics Slides: FY 2026
Anika Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 2, 2026.
Anika Therapeutics price target raised to $17 from $16 at Barrington
Barrington analyst Michael Petusky raised the firm’s price target on Anika Therapeutics (ANIK) to $17 from $16 and keeps an Outperform rating on the shares. The company reported a Q4…
Anika Therapeutics price target raised to $18 from $16 at B. Riley
B. Riley raised the firm’s price target on Anika Therapeutics (ANIK) to $18 from $16 and keeps a Buy rating on the shares. Anika Therapeutics reported strong Q4 results, with…